These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38797530)

  • 21. Axicabtagene ciloleucel for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphomas.
    Sharma P; King GT; Shinde SS; Purev E; Jimeno A
    Drugs Today (Barc); 2018 Mar; 54(3):187-198. PubMed ID: 29771253
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EMA Review of Axicabtagene Ciloleucel (Yescarta) for the Treatment of Diffuse Large B-Cell Lymphoma.
    Papadouli I; Mueller-Berghaus J; Beuneu C; Ali S; Hofner B; Petavy F; Tzogani K; Miermont A; Norga K; Kholmanskikh O; Leest T; Schuessler-Lenz M; Salmonson T; Gisselbrecht C; Garcia JL; Pignatti F
    Oncologist; 2020 Oct; 25(10):894-902. PubMed ID: 32339368
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma.
    Sim AJ; Jain MD; Figura NB; Chavez JC; Shah BD; Khimani F; Lazaryan A; Krivenko G; Davila ML; Liu HD; Falchook AD; Dahiya S; Rapoport AP; Kim S; Locke FL; Robinson TJ
    Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1012-1021. PubMed ID: 31175906
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CAR T cell therapy for B-cell lymphomas.
    Chavez JC; Locke FL
    Best Pract Res Clin Haematol; 2018 Jun; 31(2):135-146. PubMed ID: 29909914
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of
    Shouval R; Alarcon Tomas A; Fein JA; Flynn JR; Markovits E; Mayer S; Olaide Afuye A; Alperovich A; Anagnostou T; Besser MJ; Batlevi CL; Dahi PB; Devlin SM; Fingrut WB; Giralt SA; Lin RJ; Markel G; Salles G; Sauter CS; Scordo M; Shah GL; Shah N; Scherz-Shouval R; van den Brink M; Perales MA; Palomba ML
    J Clin Oncol; 2022 Feb; 40(4):369-381. PubMed ID: 34860572
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma.
    Halford Z; Anderson MK; Bennett LL
    Ann Pharmacother; 2021 Mar; 55(3):390-405. PubMed ID: 32698673
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A second round of anti-CD19 CAR T-cell therapy in diffuse large B-cell lymphoma: when persistence pays off.
    Leroy M; Deramoudt L; Pinturaud M; Demaret J; Alidjinou EK; Nudel M; Cavalieri D; Chahla WA; Odou P; Morschhauser F; Yakoub-Agha I; Simon N; Beauvais D
    Leuk Lymphoma; 2024 Jun; 65(6):868-871. PubMed ID: 38440954
    [No Abstract]   [Full Text] [Related]  

  • 28. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
    Pehlivan KC; Duncan BB; Lee DW
    Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel CAR T cell therapies for patients with large B cell lymphoma.
    Goto H; Onozawa M; Teshima T
    Int J Hematol; 2024 Jul; 120(1):6-14. PubMed ID: 38795249
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.
    Kochenderfer JN; Dudley ME; Kassim SH; Somerville RP; Carpenter RO; Stetler-Stevenson M; Yang JC; Phan GQ; Hughes MS; Sherry RM; Raffeld M; Feldman S; Lu L; Li YF; Ngo LT; Goy A; Feldman T; Spaner DE; Wang ML; Chen CC; Kranick SM; Nath A; Nathan DA; Morton KE; Toomey MA; Rosenberg SA
    J Clin Oncol; 2015 Feb; 33(6):540-9. PubMed ID: 25154820
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The promise of CAR T-cell therapy in aggressive B-cell lymphoma.
    Nair R; Neelapu SS
    Best Pract Res Clin Haematol; 2018 Sep; 31(3):293-298. PubMed ID: 30213399
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Axicabtagene Ciloleucel versus Tisagenlecleucel for Relapsed or Refractory Large B Cell Lymphoma: A Systematic Review and Meta-Analysis.
    Gagelmann N; Bishop M; Ayuk F; Bethge W; Glass B; Sureda A; Pasquini MC; Kröger N
    Transplant Cell Ther; 2024 Jun; 30(6):584.e1-584.e13. PubMed ID: 38281590
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chimeric antigen receptor modified T cell therapy in B cell non-Hodgkin lymphomas.
    Levin A; Shah NN
    Am J Hematol; 2019 May; 94(S1):S18-S23. PubMed ID: 30652353
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.
    Cappell KM; Sherry RM; Yang JC; Goff SL; Vanasse DA; McIntyre L; Rosenberg SA; Kochenderfer JN
    J Clin Oncol; 2020 Nov; 38(32):3805-3815. PubMed ID: 33021872
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adenovirus-induced hemorrhagic cystitis after CD19-targeted chimeric antigen receptor T-cell therapy in a patient with large B-cell lymphoma.
    Medina I; Carpio C; Ruiz-Camps I; Albasanz-Puig A; Lopez-Godino O; Esperalba J; Beas F; Sanchez-Salinas M; Iacoboni G; Barba P
    Immunotherapy; 2023 Nov; 15(16):1369-1374. PubMed ID: 37718888
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD19-directed CART therapy for T-cell/histiocyte-rich large B-cell lymphoma.
    Pophali PA; Fein JA; Ahn KW; Allbee-Johnson M; Ahmed N; Awan FT; Farhan S; Grover NS; Hilal T; Iqbal M; Maakaron J; Modi D; Nasrollahi E; Schachter LG; Sauter C; Hamadani M; Herrera A; Shouval R; Shadman M
    Blood Adv; 2024 Oct; 8(20):5290-5296. PubMed ID: 38985302
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the US.
    Oluwole OO; Liu R; Diakite I; Feng C; Patel A; Nourhussein I; Snider JT; Locke FL
    J Med Econ; 2022; 25(1):541-551. PubMed ID: 35443867
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Research Progress of CAR-T Cell Immunotherapy in B-Cell Non-Hodgkin's Lymphoma--Review].
    Wang MY; Tian C
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Jun; 32(3):970-973. PubMed ID: 38926998
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity.
    Locke FL; Siddiqi T; Jacobson CA; Ghobadi A; Ahmed S; Miklos DB; Perales MA; Munoz J; Fingrut WB; Pennisi M; Gauthier J; Shadman M; Gowda L; Mirza AS; Abid MB; Hong S; Majhail NS; Kharfan-Dabaja MA; Khurana A; Badar T; Lin Y; Bennani NN; Herr MM; Hu ZH; Wang HL; Baer A; Baro E; Miao H; Spooner C; Xu H; Pasquini MC
    Blood; 2024 Jun; 143(26):2722-2734. PubMed ID: 38635762
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
    Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T
    Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.